CD34⁺ CD38⁻ and CD34⁺ HLA-DR⁻ cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation

References

• Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84–92
   PubMedGoogle Scholar
• Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–9
   PubMed Web of Science ®Google Scholar
• Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–77
   PubMed Web of Science ®Google Scholar
• Osawa M, Hanada K, Hamada H, Nakauchi H. Long-term lymphohematopoietic reconstitution by a single CD34− low/negative hematopoietic stem cell. Science 1996; 273: 242–5
   PubMed Web of Science ®Google Scholar
• Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002–12
   PubMed Web of Science ®Google Scholar
• Baum CM, Weissman IL, Tsukamoto AS, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992; 89: 2804–8
   PubMed Web of Science ®Google Scholar
• Zubair A, Zahrieh D, Daley H, et al. Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion 2003; 43: 614–21
   PubMed Web of Science ®Google Scholar
• Zubair AC, Zahrieh D, Daley H, et al. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion 2004; 44: 253–61
   PubMed Web of Science ®Google Scholar
• Freedman AS, Gribben JG, Neuberg D, et al. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996; 88: 2780–6
   PubMed Web of Science ®Google Scholar
• Freedman AS, Takvorian T, Anderson KC, et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784–91
   PubMed Web of Science ®Google Scholar
• Thomas ED, Storb R. Technique for human marrow grafting. Blood 1970; 36: 507–15
   PubMed Web of Science ®Google Scholar
• Bast RC, Jr, Ritz J, Lipton JM, et al. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res 1983; 43: 1389–94
   PubMed Web of Science ®Google Scholar
• Takvorian T, Canellos GP, Ritz J, et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. New Engl J Med 1987; 316: 1499–505
   PubMed Web of Science ®Google Scholar
• Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213–26
   PubMedGoogle Scholar
• Iscove NN, Sieber F, Winterhalter KH. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol 1974; 83: 309–20
   PubMed Web of Science ®Google Scholar
• Duggan PR, Guo D, Luider J, et al. Predictive factors for long-term engraftment of autologous blood stem cells. Bone Marrow Transplantation 2000; 26: 1299–304
   PubMed Web of Science ®Google Scholar
• Lanza F, Campioni D, Moretti S, et al. CD34(+) cell subsets and long-term culture colony-forming cells evaluated on both autologous and normal bone marrow stroma predict long-term hematopoietic engraftment in patients undergoing autologous peripheral blood stem cell transplantation. Exp Hematol 2001; 29: 1484–93
   PubMed Web of Science ®Google Scholar
• Pratt G, Rawstron AC, English AE, et al. Analysis of CD34+ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total CD34+ cell dose, but steady state levels do not correlate with bone marrow reserve. Br J Haematol 2001; 114: 937–43
   PubMed Web of Science ®Google Scholar
• Sumikuma T, Shimazaki C, Inaba T, et al. CD34+/CD90+ cells infused best predict late haematopoietic reconstitution following autologous peripheral blood stem cell transplantation. Br J Haematol 2002; 117: 238–44
   PubMed Web of Science ®Google Scholar
• Meldgaard Knudsen L, Jensen L, et al. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Haematologica 1999; 84: 517–24
   PubMed Web of Science ®Google Scholar
• Stewart DA, Guo D, Luider J, et al. Factors predicting engraftment of autologous blood stem cells: CD34+ subsets inferior to the total CD34+ cell dose. Bone Marrow Transplant 1999; 23: 1237–43
   PubMed Web of Science ®Google Scholar
• Amigo ML, del Canizo MC, Caballero MD, et al. Factors that influence long-term hematopoietic function following autologous stem cell transplantation. Bone Marrow Transplant 1999; 24: 289–93
   PubMed Web of Science ®Google Scholar
• Freedman A, Neuberg D, Mauch P, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood 1997; 90: 4996–5001
   PubMed Web of Science ®Google Scholar
• To L, Haylock D, Simmons P, Juttner C. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233–58
   PubMed Web of Science ®Google Scholar
• Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–94
   PubMed Web of Science ®Google Scholar
• Koumakis G, Vassilomanolakis M, Hatzichristou H, et al. Predictive factors affecting mobilization and peripheral blood stem cell (PBSC) collection using single apheresis (SA) for rescuing patients after high-dose chemotherapy (HD.CHE) in various malignancies. Bone Marrow Transplant 1996; 18: 1065–72
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Wallmeier M, et al. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997; 98: 736–44
   PubMed Web of Science ®Google Scholar
• Martin A, Perez-Simon JA, Caballero MD, et al. Effect of pre-transplant cumulative doses of chemotherapeutic drugs on early and long-term hematological recovery after autologous bone-marrow transplantation for lymphoma. Haematologica 2005; 90: 78–85
   PubMed Web of Science ®Google Scholar
• Bast RC, Jr, De Fabritiis P, Lipton J, et al. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res 1985; 45: 499–503
   PubMed Web of Science ®Google Scholar
• De Fabritiis P, Bregni M, Lipton J, et al. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood 1985; 65: 1064–70
   PubMed Web of Science ®Google Scholar
• Stewart DA, Guo D, Luider J, et al. The CD34+90+ cell dose does not predict early engraftment of autologous blood stem cells as well as the total CD34+ cell dose. Bone Marrow Transplant 2000; 25: 435–40
   PubMed Web of Science ®Google Scholar
• Gonzalez-Requejo A, Madero L, Diaz MA, et al. Progenitor cell subsets and engraftment kinetics in children undergoing autologous peripheral blood stem cell transplantation. Br J Haematol 1998; 101: 104–10
   PubMed Web of Science ®Google Scholar
• Donaldson C, Denning-Kendall P, Bradley B, Hows J. The CD34(+)CD38(neg) population is significantly increased in haemopoietic cell expansion cultures in serum-free compared to serum- replete conditions: dissociation of phenotype and function. Bone Marrow Transplant 2001; 27: 365–71
   PubMed Web of Science ®Google Scholar
• Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. Science 2001; 294: 1933–6
   PubMed Web of Science ®Google Scholar
• Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048–57
   PubMed Web of Science ®Google Scholar
• Korbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter?. Blood. 2001; 98: 2900–2908
   PubMed Web of Science ®Google Scholar
• Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury [comments]. J Clin Oncol 1999; 17: 423–9
   PubMed Web of Science ®Google Scholar
• Prosper F, Stroncek D, McCarthy JB, Verfaillie CM. Mobilization and homing of peripheral blood progenitors is related to reversible downregulation of alpha4 beta1 integrin expression and function. J Clin Invest 1998; 101: 2456–67
   PubMed Web of Science ®Google Scholar
• Aiuti A, Webb IJ, Bleul C, et al. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111–20
   PubMed Web of Science ®Google Scholar
• Ramirez M, Regidor C, Marugan I, Garcia-Conde J, Bueren JA, Fernandez MN. Engraftment kinetics of human CD34+ cells from cord blood and mobilized peripheral blood co-transplanted into NOD/SCID mice. Bone Marrow Transplant 2005; 35: 271–275
   PubMed Web of Science ®Google Scholar